Navigation Links
Researchers use 'trickery' to create immune response against melanoma

Ground-breaking results from researchers at Harvard Medical School and Massachusetts Institute of Technology (MIT), USA, disclosed at the 13th European Cancer Conference (ECCO) have shown for the first time that targeted drug delivery is possible using nanoparticle-apatamer conjugates.

Nucleic acid ligands (referred to as aptamers) are short DNA or RNA fragments that can bind to target antigens with high specificity and affinity; analogous to monoclonal antibodies. In the field of cancer nanotechnology, aptamers have the potential to act as targeting molecules - directing the delivery of nanoparticles to tumour-antigens, present on the surface of cancer cells. In general terms, therapeutic nanoparticles (~50 ?~250 nanometer) are specially designed delivery vehicles that can encapsulate a drug within them and release the drug in a pre-determined and regulated manner which can vary from a sudden release to a slow release over a period of several years. Using prostate cancer as a model disease, proof of concept nanoscale targeted drug delivery vehicles were developed (1 nanometer = 0.000000001 meter), which can target prostate cancer cells with high specificity and efficiency. Once bound to prostate cancer cells, the nanoparticle/aptamer bioconjugates were internalised making it possible for their cytotoxic payload to get released directly inside the cancer cells. The combination of targeted delivery and controlled release of drugs at the site of cancer will likely result in "smart therapeutics" that are more effective, yet safer than what is available today.

As the initial step, researchers synthesised nanoparticles for controlled drug release made from a biocompatible and biodegradable PLA polymer system and encapsulated a fluorescently labeled model drug within them, in order to visualise nanoparticle uptake into target cells. The nanoparticles in question were designed for attachment to aptamers so that the binding properties of aptamers for targeti
'"/>

Source:University of Pittsburgh Medical Center


Page: 1 2 3 4

Related biology news :

1. Researchers discover way to make cells in the eye sensitive to light
2. Researchers find how protein allows insects to detect and respond to pheromones
3. Researchers Uncover Key Step In Manufacture of Memory Protein
4. Researchers reveal the infectious impact of salmon farms on wild salmon
5. Researchers identify target for cancer drugs
6. Researchers discover molecule that causes secondary stroke
7. Researchers find missing genes of ancient organism
8. Researchers trace evolution to relatively simple genetic changes
9. Researchers add new tool to tumor-treatment arsenal
10. UF Researchers Map Bacterial Proteins That Cause Tooth Loss
11. VCU Researchers Identify Networks Of Genes Responding To Alcohol In The Brain

Post Your Comments:
(Date:11/23/2009)...hern California biomedical engineer and cardiologi...to help clinicians distinguish cardiac emergencies... manageable with drugs and lifestyle change. , A...the arteries feeding the heart, offer an inside vi...d vessels, often revealing deposits of a dangerous...
(Date:11/23/2009)...te of General Medical Sciences (NIGMS), part of th...g $42.3 million for grants in scientific areas it ...loped the GO grant program to stimulate biomedical...the American Recovery and Reinvestment Act (Recove...mise to have a significant impact on a field of bi...
(Date:11/23/2009)...sabona is Director of the Interuniversity Professo...rsity and the University of the Basque Country. Th...also has other experts such as researchers in the ...cialists in ethics. , The Interuniversity Profes...sities of Deusto and the Basque Country was create...
Breaking Biology News(10 mins):Stable plaque or heart attack plaque? USC researcher builds new sensor to tell which is which 2NIGMS invests in scientific Grand Opportunities with Recovery Act funds 2NIGMS invests in scientific Grand Opportunities with Recovery Act funds 3Research and legislation should go hand in hand, as much as possible 2Waters Drives Efficiency in the Clinical and Research Laboratory and Showcases New MassTrak Systems at AACC 2009 52119 1Waters Drives Efficiency in the Clinical and Research Laboratory and Showcases New MassTrak Systems at AACC 2009 52119 2Waters Drives Efficiency in the Clinical and Research Laboratory and Showcases New MassTrak Systems at AACC 2009 52119 3Waters Drives Efficiency in the Clinical and Research Laboratory and Showcases New MassTrak Systems at AACC 2009 52119 4Promising new treatment for Alzheimers suggested based on Hebrew University research 9283 1Promising new treatment for Alzheimers suggested based on Hebrew University research 9283 2Slotted buses keep passengers cool 9279 1Slotted buses keep passengers cool 9279 2
...ruggling with what humans have done to the modern ... according to Professor Greg Gibson,s recently pub... Between Our Genes and Modern Life Is Making Us Si...cal Sciences, suggests the increased rates of dise...due to human genes being unable to cope with the 2...
...MIPAS and GOME-2 instruments, scientists have for ...in the atmosphere. These new measurements will hel...-depleting species and to improve simulations of s...tion of bromine monoxide (BrO) in the atmosphere s...st observed in 2008 when scientists from the Karls...
...Biometric Technology In Support of the Warfighter ...pplications International Corporation (NYSE: SAI...ct by Sensor Technologies Incorporated (STI) to su... Command (CECOM) by providing operations and user ... (TBS). SAIC,s subcontract has a one-year base pe...
Other Biology News:'It takes a genome: How a clash between our genes and modern life is making us sick' 2European satellites provide new insight into ozone-depleting species 2SAIC Awarded $115 Million Subcontract to Support Tactical Biometrics Systems (TBS) 2
(Date:11/19/2009)...., Nov. 19 Spherix Incor...ology for diabetes therapy, and a provider of tech...supplement, biotechnology and pharmaceutical compa...orted $6.3 million registered direct placement to ... common stock and warrants to purchase up to 1,104...
(Date:11/19/2009)...THAM, Mass., Nov. 19 Arlington Med...hat the leading driver of antibiotic selection in ...ctivity against gram-positive and gram-negative pa...cause nosocomial pneumonia, surveyed European phys...that provide appropriate coverage against common p...
(Date:11/19/2009)... surgeons and recognized refractive and cataract s...de brought their fellow surgeons up-to-date on the... cataract surgery, and ophthalmology in general at...lmology (AAO) annual meeting in San Francisco, Cal..., Dr. David Huang, MD, Dr. Randy Epstein, Dr. Will...
(Date:11/19/2009)... November 19 AFFiRiS AG will focus...ndidate at an unexpectedly early,stage of developm...r into,Phase II clinical trial early in 2010. This...ompletion of two Phase I trials with the candidate...on on the first interim,analysis of the secondary ...
Breaking Biology Technology:Spherix Announces the Closing of $6.3 Million Registered Direct Offering 2Spherix Announces the Closing of $6.3 Million Registered Direct Offering 3Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 3Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 2Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 3Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 4Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 5Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 6Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 7Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 8Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 9AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 2AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 3
...M), a developer of follow-on biologics and biophar...nd questionnaire from the Chairman and,Ranking Mem...ttee on Health,on the possible development of legi...regulatory pathway., Sent to approximately 30 sta... and patient communities, the letter notes that th...
...date -, PRINCETON, N.J., April 10, 2008 Laureate...elopment and protein production,company, today ann...nufacturing agreement with Alopexx Pharmaceuticals...roduce Alopexx,s mAb F598 antibody under cGMP,cond...al trials, and later,for commercial production for...
...y become easier, thanks to chemical sensors being ... led by chemistry professor Theodore Goodson III h...ff signals that can be detected remotely---from a ...y described in the journal Nanotechnology and also...ional meeting of the American Chemical Society in ...
Other Biology Technology:Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway 2Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway 3Laureate Pharma Announces Manufacturing Agreement With Alopexx Pharmaceuticals, LLC 2Laureate Pharma Announces Manufacturing Agreement With Alopexx Pharmaceuticals, LLC 3Safer, easier system for remote explosive detection 2
...r real-time or pre-programmed liquid switching in ...y, or general liquid-handling research application...econd accuracy Run experiments automatically - ev...nd flexibility Turnkey perfusion system includes ...
Human PTP1B, aa 2-321 Carrier Free from R&D Systems
... the basic components required for the development...nant rat Thymus Chemokine-1 in cell culture supern...ials to run ELISAs on approximately fifteen 96-wel...re met: The assay is run as summarized in the Ge...
Anti-FGF Receptor 1 Antibody, Unconjugated from Cell Signaling Technology
Biology Products: